Table 1.
Select characteristics of breast cancer cases, overall and by race, N = 2,998
| Overall (N = 2,998) | Black (n = 2,227) | White (n = 771) | |
|---|---|---|---|
|
| |||
| Sociodemographic and clinical/reproductive characteristics | n (%) | n (%) | n (%) |
|
| |||
| Age (years), mean±SD | 53.3±10.6 | 53.6±10.8 | 52.1±9.9 |
| Education | |||
| Less than 12th grade | 257 (8.6) | 235 (10.5) | 22 (2.9) |
| High school graduate or equivalent | 789 (26.3) | 660 (29.7) | 129 (16.7) |
| Some college | 838 (28.0) | 669 (30.0) | 169 (21.9) |
| College graduate | 639 (21.3) | 404 (18.2) | 235 (30.5) |
| Post-graduate | 473 (15.8) | 257 (11.6) | 216 (28.0) |
| Insurance | |||
| Medicare | 375 (12.6) | 310 (14.0) | 65 (8.4) |
| Medicaid | 335 (11.2) | 307 (13.9) | 28 (3.6) |
| Private | 1,792 (60.2) | 1,213 (54.9) | 579 (75.3) |
| Uninsured | 344 (11.6) | 278 (12.5) | 66 (8.7) |
| Other | 132 (4.4) | 101 (45.7) | 31 (4.0) |
| Body mass index (kg/m2), mean ± SD | 30.5±7.1 | 31.7±7.0 | 27.1±6.4 |
| Body mass index (kg/m2) | |||
| 18.5–24.99 | 734 (24.4) | 381 (17.1) | 353 (45.8) |
| 25.0–29.99 | 836 (27.9) | 628 (28.2) | 208 (27.0) |
| 30.0–34.99 | 708 (23.6) | 592 (26.6) | 116 (15.0) |
| ≥35.0 | 720 (24.1) | 626 (28.1) | 94 (12.2) |
| History of benign breast disease | |||
| No | 1,055 (35.4) | 1,480 (66.9) | 442 (57.8) |
| Yes | 1,922 (64.6) | 733 (33.1) | 322 (42.2) |
| Initial mode of breast cancer detection | |||
| Routine mammography | 1,405 (47.1) | 1000 (45.1) | 405 (52.7) |
| Clinical breast exam/routine physical exam by healthcare provider | 129 (4.3) | 83 (3.7) | 46 (6.0) |
| Self-detection/accidental discovery | 1,034 (34.6) | 794 (35.8) | 240 (31.3) |
| Other | 418 (14.0) | 341 (15.4) | 77 (10.0) |
| Family history of breast cancer | |||
| No | 2,435 (81.2) | 1,843 (82.7) | 592 (76.8) |
| Yes | 563 (18.8) | 384 (17.3) | 179 (23.2) |
| Age at menarche (years), mean±SD | 12.5±1.8 | 12.5±1.9 | 12.5±1.5 |
| Parity | |||
| Nulliparous | 602 (20.1) | 359 (16.1) | 243 (37.1) |
| 1–2 | 1,499 (50.0) | 1,139 (51.1) | 360 (54.9) |
| ≥3 | 897 (29.9) | 729 (32.8) | 52 (8.0) |
| History of oral contraceptive use | |||
| No | 1,009 (33.7) | 740 (33.3) | 269 (35.0) |
| Yes | 1,984 (66.3) | 1,484 (66.7) | 500 (65.0) |
| History of hormone replacement therapy | |||
| No | 2,455 (82.3) | 1,880 (85.0) | 575 (74.6) |
| Yes | 528 (17.7) | 332 (15.0) | 196 (25.4) |
|
| |||
| Tumor clinicopathologic features | |||
|
| |||
| Tumor grade | |||
| Well differentiated | 364 (14.7) | 231 (12.2) | 133 (22.9) |
| Moderately differentiated | 1,042 (42.2) | 786 (41.6) | 256 (44.1) |
| Poorly differentiated | 1,064 (43.1) | 873 (46.2) | 191 (33.0) |
| Tumor size | |||
| <1.0 cm | 1,416 (47.2) | 994 (44.6) | 422 (54.7) |
| 1.0–2.0 cm | 832 (27.8) | 608 (27.3) | 224 (29.1) |
| >2.0 cm | 750 (25.0) | 625 (28.1) | 125 (16.2) |
| AJCC stage | |||
| Stage 0 | 497 (18.9) | 362 (18.4) | 135 (20.6) |
| Stage I | 1,014 (38.6) | 705 (35.8) | 309 (47.2) |
| Stage II | 791 (30.1) | 634 (32.2) | 157 (24.0) |
| Stage III | 272 (10.4) | 227 (11.5) | 45 (6.9) |
| Stage IV | 52 (2.0) | 43 (2.1) | 9 (1.3) |
| ER status | |||
| Positive | 1,985 (73.7) | 1,450 (71.3) | 535 (80.9) |
| Negative | 709 (26.3) | 583 (28.7) | 126 (19.1) |
| HER2 status | |||
| Positive | 483 (21.0) | 380 (21.6) | 103 (19.0) |
| Negative | 1,783 (77.4) | 1,355 (77.0) | 428 (78.8) |
| Equivocal | 37 (1.6) | 25 (1.4) | 12 (2.2) |
| PR status | |||
| Positive | 1,501 (56.6) | 1,089 (54.1) | 412 (64.4) |
| Negative | 1,153 (43.4) | 925 (45.9) | 228 (35.6) |
| Lymph node status | |||
| Positive | 737 (31.5) | 589 (32.8) | 148 (27.2) |
| Negative | 1,601 (68.5) | 1,206 (67.2) | 395 (72.8) |
| Tumor subtype | |||
| Luminal A | 1,311 (58.9) | 955 (55.8) | 365 (69.5) |
| HER2-positive | 471 (21.2) | 375 (21.9) | 96 (18.8) |
| Triple-negative | 442 (19.9) | 382 (22.3) | 60 (11.7) |